RESMED INC
For the period ended Sep 30, 2024. Filed Oct 25, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 25, 2024
RMD$234.11-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
| PART I – FINANCIAL INFORMATION | Item 1 |
|---|
Condensed Consolidated Statements of Cash Flows (Unaudited)
| Three Months EndedSeptember 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net income | $311,355 | $219,422 |
| Adjustment to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 44,730 | 44,934 |
| Amortization of right-of-use assets | 8,980 | 8,508 |
| Stock-based compensation costs | 20,156 | 18,510 |
| (Gain) loss attributable to equity method investments (note 5) | (963) | 3,895 |
| (Gain) loss on equity investments (note 5) | 680 | 602 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 36,417 | 6,534 |
| Inventories | (70,254) | 26,911 |
| Prepaid expenses, net deferred income taxes and other current assets | (123) | (42,015) |
| Accounts payable, accrued expenses, income taxes payable and other | (25,440) | (1,018) |
| Net cash provided by (used in) operating activities | 325,538 | 286,283 |
| Cash flows from investing activities: | ||
| Purchases of property, plant and equipment | (17,840) | (30,035) |
| Patent registration and acquisition costs | (1,767) | (10,831) |
| Business acquisitions, net of cash acquired | — | (103,183) |
| Purchases of investments (note 5) | (1,350) | (3,680) |
| Proceeds from exits of investments (note 5) | 4,128 | 250 |
| Proceeds (payments) on maturity of foreign currency contracts | 18,975 | (1,501) |
| Net cash provided by (used in) investing activities | 2,146 | (148,980) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, net | 8,383 | 983 |
| Taxes paid related to net share settlement of equity awards | (389) | (225) |
| Purchases of treasury stock | (50,005) | — |
| Payments of business combination contingent consideration | (855) | (1,293) |
| Proceeds from borrowings, net of borrowing costs | — | 105,000 |
| Repayment of borrowings | (30,000) | (185,000) |
| Dividends paid | (77,891) | (70,597) |
| Net cash provided by (used in) financing activities | (150,757) | (151,132) |
| Effect of exchange rate changes on cash | 11,073 | (4,962) |
| Net increase (decrease) in cash and cash equivalents | 188,000 | (18,791) |
| Cash and cash equivalents at beginning of period | 238,361 | 227,891 |
| Cash and cash equivalents at end of period | $426,361 | $209,100 |
| Supplemental disclosure of cash flow information: | ||
| Income taxes paid, net of refunds | $105,704 | $76,749 |
| Interest paid | $7,351 | $14,957 |
| Fair value of assets acquired, excluding cash | $— | $34,092 |
| Liabilities assumed | — | (5,325) |
| Goodwill on acquisition | — | 74,416 |
| Fair value of contingent consideration | 855 | 1,293 |
| Cash paid for acquisitions | $855 | $104,476 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.